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Abstract
Following the successful cloning of receptor for SARS coronavirus a few years ago, Dr. Wenhui Li and colleagues
raised attention again by publishing a possible receptor for hepatitis B virus in eLife. We will briefly review the
significance of this finding and the future prospects of hepatitis B research.
Among the five hepatotropic hepatitis viruses, only
hepatitis B virus (HBV) and its satellite hepatitis D virus
(HDV) still wait for the development of an in vitro infec-
tion system in cell culture. One hepatocellular carcin-
oma (HCC) cell line, HepaRG, can be infected at a
modest efficiency after weeks of culture and induced dif-
ferentiation [1]. Even primary human hepatocytes rapidly
lose the capacity for HBV infection after brief cell cul-
ture. The HBV infection demands both intracellular and
cell-surface factors. The intracellular requirements ap-
pear less stringent, as after transfection of HBV DNA
into many HCC cell lines or mouse liver, which cannot
be infected naturally, the viral genome is expressed and
replicates actively. Thus, the failure of HBV infection is
considered largely to be due to strict restriction on the
interaction between HBV virions and the cell membrane.
The molecules on the cell membrane needed for HBV in-
fection can be divided into two classes: low affinity and high
affinity molecules. Among others, the heparan sulfates in
the membrane proteins mediate the broad, but less specific,
virus-cell interaction. However, the high affinity membrane
partners for HBV remain elusive (the carboxypeptidase D
found for duck hepatitis B virus may be the only serious
contender [2]).
HBV envelope protein, namely the surface antigens, plays
an essential role in the infection process. Both genetic and
functional examination identified one domain in the N-
terminus of HBV preS1 (amino acids 1–47) necessary for in-
fection. This domain has been shown to function as a direct
mediator for HBV by binding presumably cellular corre-
sponding receptor(s) [3]. More importantly, the myristoy-
lated peptide is shown to effectively block HBV infection in
primary human hepatocytes and in the human hepatocyte-
chimera mouse at a nanomolar concentration [4]. In fact, a
clinical trial testing the efficacy of this peptide in preventing
HBV infection has been ongoing [5]. Clearly, this preS1 pep-
tide can be a useful probe to pull out the interacting cellular
factors, including specific viral receptors.
Yan et al. have taken a reasonable approach to fish out
possible HBV receptor(s) [6]. They engineered the first 2–47
amino acid peptide from PreS1 to increase its capacity to be
cross-linked with proteins interacting with the cell mem-
brane, without affecting its binding specificity. In order to
obtain sufficient materials after cross-linking, they adopted
the Tupaia hepatocytes, instead of human hepatocytes, for
the experiments. The strategies actually brought down many
membrane proteins, but in comparison with the negative
control (homologous peptide without specific binding), they
identified one cellular protein, NTCP (sodium taurocholate
cotransporting peptide) by LC/MS/MS. The same protein
was pulled down from human hepatocytes as well. The
authors further produced HCC cell lines stably expressing
NTCP and subsequently infected them with HBV or HDV.
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Immunofluorescence staining clearly demonstrated the ex-
pression of HBV and HDV proteins in these cell lines, sug-
gestive of a successful viral infection. In addition, they
documented a 2-4-fold increase of viral RNA and DNA after
infection in the cell line by real-time PCR. They also showed
a Southern blot supporting the presence of HBV covalently
closed circular DNA in the infected cell, a well-recognized
marker for productive HBV infection. Finally, they identified
a stretch of 10 amino acids in the NTCP transmembrane do-
main, as the motif directly interacting with the PreS1 peptide.
NTCP is a transmembrane protein, usually located in the
lateral surface (canalicular) of hepatocytes, which mediates
bile acid transport [7]. Geographically, it is a good candidate
for an HBV receptor. Moreover, the authors could convert
the cell lines previously non-permissible to HBV infection
to permissible by over-expression of NTCP, again support-
ing its possible role in the HBV infection process. This can
be a critical and long-awaited discovery toward understand-
ing HBV receptors and establishing an experimental HBV
infection system.
Looking forward, we need to understand how NTCP
interacts with both HBV envelope proteins and with other
cellular proteins, especially through the motif embedded
in the cell membrane. NTCP itself is not sufficient to
allow HBV infection, as the majority of HepaRG cells were
found to express NPCT but not to be infected [8]. NTCP
might initiate or mediate molecular interactions that can
overcome the cell-surface restrictions for viral entry. Such
cooperative cellular or viral factors have to be discovered
and demonstrated to enhance the efficiency of viral infec-
tion, at a level comparable to a natural one (hundreds or
thousands fold viral amplification). For example, the
authors can use the NTCP-expressing cell lines as the start-
ing materials to systemically identify other factors (maybe
carboxypeptidase D) and make these cell lines more pro-
ductive and permissive to HBV infection. In the near future,
standard virological assays for HBV infections, including
Northern or Western blots, are expected to demonstrate
the successful HBV infections in vitro.
The HBV research community has searched for HBV
receptors for decades. Many candidates have been discov-
ered and then discarded. The current study, however, took
advantage of a well-documented viral peptide required for
HBV entry in combination with a state-of-the-art proteo-
mics platform. As a Chinese proverb says “a thousand-mile
journey starts from one incremental step”. As such, the
identification of NTCP as a potential viral receptor for
HBV may serve as an important initial step for this journey,
leading to the development of an HBV infection system to
facilitate the HBV research and hepatitis B treatment.
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